An investment in health and social responsibility
Prevention is the first step in saving lives, but Italy still lacks a widespread culture of early detection of urinary tract cancers. Unlike Pap tests and mammograms, there is no public screening program for these diseases, which account for more than 8 percent of cancers diagnosed in our country. Today, companies have an opportunity to fill this gap by offering their employees an innovative service: Urine24, the urinary cytology test from Hospitex International.
What is Urine24?
Urine24 is a voluntary, noninvasive screening service for urinary tract cancers (kidney, bladder, ureter, urethra). The test is delivered through an easy-to-use kit, which includes:
- 3 urine collection bottles with CYTOfast fixative;
- Instructions and information for proper use;
- Sample pick-up service at home or at the company;
- Thin-layer cytology analysis with advanced technology;
- Reporting with The Paris System II method, an international standard of accuracy;
- Emailing the report directly to the patient.
In this way, the examination becomes quick, reliable and affordable, without loss of working days and with full logistical support.
- 3 urine collection bottles with CYTOfast fixative;
- Instructions and information for proper use;
- Sample pick-up service at home or at the company;
- Thin-layer cytology analysis with advanced technology;
- Reporting with The Paris System II method, an international standard of accuracy;
- Emailing the report directly to the patient.
In this way, the examination becomes quick, reliable and affordable, without loss of working days and with full logistical support.
Why it is important
Early diagnosis of urinary tract cancers can make the difference between successful treatment and delayed diagnosis. Identifying any cellular changes early significantly increases the chances of treatment and cure. Thus, investing in prevention means protecting people's health while generating a positive impact on business life.
The benefits for companies
Purchasing and distributing Urine24 kits to employees is not only an act of health protection but also a strategic choice:
- Health and wellness: reduces sick leave and promotes productivity.
- Corporate reputation: strengthens social responsibility image, improves employee branding and increases internal satisfaction.
- ESG and CSR performance: contributes to sustainability and employee care goals.
- Practical benefits: easy-to-use kit, digital reports, and full cost deductibility as part of corporate welfare.
With Urine24, companies become active players in the fight against cancer, setting a concrete example of ethical and social leadership.
- Health and wellness: reduces sick leave and promotes productivity.
- Corporate reputation: strengthens social responsibility image, improves employee branding and increases internal satisfaction.
- ESG and CSR performance: contributes to sustainability and employee care goals.
- Practical benefits: easy-to-use kit, digital reports, and full cost deductibility as part of corporate welfare.
With Urine24, companies become active players in the fight against cancer, setting a concrete example of ethical and social leadership.
Hospitex International
Behind the Urine24 project is Hospitex International, an innovative SME based in Sesto Fiorentino, Italy. With more than 50 years of experience in in vitro diagnostics, Hospitex develops and manufactures instruments for medical laboratories worldwide, with a focus on thin layer cytology and telemedicine solutions. ISO 13485 certified for medical devices, the company combines research, technology and social commitment to make oncology diagnostics globally accessible.
Conclusion
Integrating Urine24 into corporate welfare policies means investing in people's health and the future of the company. Each kit distributed represents not only a prevention tool, but also a clear message: the lives and well-being of workers are a priority.
